HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an eLetter View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Related articles in BJP Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by KEKS, N. A. Articles by KARCHER, K. Search for Related Content PubMed PubMed Citation Articles by KEKS, N. A. Articles by KARCHER, K.

Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder

Randomised, controlled, open-label study

Mental Health Research Institute of Victoria and Monash University, Victoria, Australia

MICHAEL INGHAM, MSc, AKBAR KHAN, MD and KEITH KARCHER, MSc

Johnson & Johnson Pharmaceutical Research and Development, Titusville, New Jersey, USA

Correspondence: Professor Nicholas A. Keks, Delmont Hospital, 298 Warrigal Road, Glen Iris, VIC 3146, Australia. Email: Nicholas.keks{at}med.monash.edu.au

Declaration of interest N. K. has received support from or been a consultant for AstraZeneca, Bristol-Meyers Squibb, Janssen Pharmaceutica, Eli Lilly, Sanofi-Synthelabo, Pfizer and Wyeth. M.I., A.K. and K.K. are employees of Johnson & Johnson.

Background The efficacy and safety of long-acting injectable risperidone have not been compared with those of an oral atypical antipsychotic.

Aims To compare long-acting risperidone and oral olanzapine in 377 patients with DSM–IV schizophrenia or schizoaffective disorder.

Method Patients were randomised to receive long-acting risperidone (25 mg or 50 mg every 14 days) or olanzapine (5–20 mg/day).

Results In the 13-week phase, long-acting risperidone was at least as effective as (not inferior to) oral olanzapine. In the 12-month phase, significant improvements in the Positive and Negative Syndrome Scale (PANSS) total and factor scores from baseline to month 12 and end-point were seen in both groups of patients. Few patients discontinued treatment because of an adverse event.

Conclusions Both treatments were efficacious and well tolerated.

Related articles in BJP:

Highlights of this issue

KIMBERLIE DEAN
BJP 2007 191: A5. [Full Text]